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ABSTRACT: Bone morphogenetic proteins (BMPs) are known as ectopic bone inducers. The FDA approved
BMPs (BMP2 and BMP7) for clinical use. However, direct effects of BMPs on endogenous bone metabolism
are not yet well known. We conditionally disrupted BMP receptor type IA (BMPRIA) in osteoblasts during
weanling and adult stages to show the impact of BMP signaling on endogenous bone modeling and remod-
eling. Cre recombination was detected in immature osteoblasts in the periosteum, osteoblasts, and osteocytes
but not in chondrocytes and osteoclasts after tamoxifen administration. Bmpr1a conditional knockout mice
(cKO) showed increased bone mass primarily in trabecular bone at P21 and 22 wk as determined by H&E
staining. Vertebrae, tails, and ribs showed increased radiodensity at 22 wk, consistent with a significant
increase in BMD. Both CT and histomorphometry showed an increase in trabecular BV/TV and thickness
of cKO adult bones, whereas osteoclast number, bone formation rate, and mineral apposition rate were
decreased. Expression levels of bone formation markers (Runx2 and Bsp), resorption markers (Mmp9, Ctsk,
and Tracp), and Rankl were decreased, and Opg was increased in adult bones, resulting in a reduction in the
ratio of Rankl to osteoprotegerin (Opg). The reduction in osteoclastogenesis through the RANKL–OPG
pathway was also observed in weanling stages and reproduced in newborn calvaria culture. These results
suggest that Bmpr1a cKO increased endogenous bone mass primarily in trabecular bone with decreased
osteoclastogenesis through the RANKL–OPG pathway. We conclude that BMPRIA signaling in osteoblasts
affects both bone formation and resorption to reduce endogenous bone mass in vivo.
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INTRODUCTION
BONE MORPHOGENETIC PROTEINS (BMPs) are members ofthe TGF- superfamily and were originally discovered
as ectopic bone inducers in soft tissue.(1) The osteogenic
function of BMPs has been extensively examined, mainly
using osteoblasts in culture.(2) The FDA approved some
BMPs (BMP2 and BMP7) for clinical use in long bone open
fractures, nonunions fractures, and spinal fusion. However,
despite significant evidence of their potential for bone re-
generation in animal and preclinical studies, the current clini-
cal data supporting their effectiveness are not robust.(3,4)
This may be because in part of a lack of understanding of
the variable effects BMPs have in vivo on different cell
types including chondrocytes, osteoblasts, and osteocytes.
BMP2, BMP4, and their potent receptor BMP receptor
type IA (BMPRIA or ALK3) are abundantly expressed in
the skeleton; however, conventional knockout (KO) mice
for these genes cause early embryonic lethality.(5–7) We
previously rescued the lethality of loss of Bmpr1a using the
Cre-loxP system under the control of an osteocalcin pro-
moter(8) and found that bone mass (BV/TV) evaluated by
bone histomorphometry was reduced in the mutant mice at
3 mo but was increased at 10 mo. This evidence suggests
that BMPs have diverse effects on bone mass, bone forma-
tion, and homeostasis in an age-dependent manner.
To understand age-dependent functions of BMP signal-
ing in the skeleton, it is important to disrupt BMP signaling
at different ages in an osteoblast-specific manner. Here, we
used a tamoxifen (TM)-inducible Cre-loxP system under
the control of a 3.2-kb type I collagen promoter (Col1-
CreERTM mice), which is activated in osteoblasts, odonto-
blasts, and tendon fibroblasts,(9) and disrupted BMP signal-
ing through BMPRIA in bone. This system allows us to
control the onset of the disruption of Bmpr1a in osteoblasts
at any age by administration of TM. Because peak bone
mass in the mouse is achieved after 20 wk,(10) we first fo-
cused on bone remodeling and analyzed 22-wk mice, start-
ing TM administration at 8 wk. Moreover, to identify age-
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dependent effects of BMP signaling, we also studied bone
modeling using weanling mice starting TM administration
at postnatal day 2 (P2).
In this study, we found that bone mass was increased by
loss of BMP signaling in osteoblasts through BMPRIA dur-
ing both stages. Osteoclastogenesis was reduced through
the RANKL–osteoprotegerin (OPG) pathway, even
though bone formation markers were reduced or un-
changed in the mutant mice, resulting in a net increase in
bone mass. This evidence suggests that BMP signaling in
osteoblasts restrains endogenous bone mass, which is unex-
pected and contrary to the current understanding of BMPs
as bone inducers.(1)
MATERIALS AND METHODS
Mice and TM administration
Mice expressing the TM-inducible Cre fusion protein
Cre-ERTM(11,12) under the control of a 3.2-kb mouse pro-
collagen 1(I) promoter(9) (Col1-CreERTM) were gener-
ated by pronuclear injection and crossed with floxed
Bmpr1a mice.(13) ROSA26 Cre reporter (R26R) mice were
kindly provided by Dr Philippe Soriano.(14) Col1-CreERTM
mice were crossed with floxed Bmpr1a mice(13) to generate
mice genotyped as Col1-CreERTM+:Bmpr1afx/fx and Col1-
CreERTM−:Bmpr1afx/fx. TM (T5648; Sigma) was dissolved
in a small volume of ethanol, diluted with corn oil at a
concentration of 10 mg/ml, and stored at −20°C until use.
After TM administration, Cre recombination was induced
in Bmpr1a cKO mice (Col1-CreERTM+:Bmpr1afx/fx) but
not in littermate controls (Col1-CreERTM−:Bmpr1afx/fx).
In weanling mice, TM (75 mg/kg) was injected intraperito-
neally into nursing females every 3 days from P2 until dis-
section at P14 or P21 (Fig. 1B). For adult stages, TM was
injected intraperitoneally twice a week from 8 wk until dis-
section at 10–12 or 22 wk (Fig. 1C). Results were analyzed
by comparing Bmpr1a cKO (Col1-CreERTM+, Bmpr1afx/
fx) and littermate controls (Col1-CreERTM−, Bmpr1afx/fx),
both of which received TM. No side effects on bone mor-
phology were observed using this TM regimen. The animal
protocol was approved by the Institutional Animal Care
and Use Committee at the National Institute of Environ-
mental Health Sciences, NIH.
Histology
For H&E staining, femora, tibia, humerus, tails, lumbar
vertebrae, ribs, and calvaria from P21 and 22-wk mice were
fixed in 4% paraformaldehyde, decalcified with 10%
EDTA, and embedded in paraffin. Paraffin sections were
cut in sagittal and coronal planes at 8 m. Immunostaining
was performed using rabbit polyclonal antibodies against
BMPRIA(15) (1:50; Orbigen). Subsequently, an ABC kit
(Santa Cruz Biotechnology) and DAB exposure were used
for detection. For -galactosidase (-gal) staining, decalci-
fied bones were prepared in 30% sucrose before frozen
sectioning. Sections were stained with X-gal for -gal activ-
ity and counterstained with eosin.
Static and dynamic bone histomorphometry
Adult mice received calcein (10 mg/g; Sigma) in 2%
NaHCO3 intraperitoneally 7 days before death at 22 wk
and xylenol orange (90 mg/kg; Sigma) intraperitoneally 2
days before death. Femora and vertebrae (L2 and L3) were
dissected and fixed in 4% paraformaldehyde. The undecal-
cified distal femora and vertebrae were dehydrated and
embedded in methyl methacrylate. Five-millimeter longitu-
dinal sagittal and coronal sections were cut on a Polycut S
microtome (Reichert-Jung). Sections were taken from the
middle of the femora, and vertebrae were stained with
modified Masson’s trichrome. Histomorphometric mea-
surements were made in a blinded, nonbiased manner using
the OsteoMeasure computerized image analysis system
(OsteoMetrics) interfaced with an Optiphot Nikon micro-
scope (Nikon) at a magnification of ×20. All femoral mea-
surements were confined to the secondary spongiosa and
restricted to an area between 400 and 2000 m distal to the
growth plate–metaphyseal junction of the distal femur.
For TRACP staining, decalcified lumbar (L3) 5-m par-
affin sections were prepared as described for H&E staining.
Sections were stained using the leukocyte acid phosphatase
kit (Sigma) and counterstained with hematoxylin. Osteo-
clasts were identified as multinucleated, TRACP+ cells lin-
ing the trabeculae. All measurements were made as de-
scribed for bone histomorphometry.
X-ray, µCT, and DXA analyses
X-ray images of P21 and 22-wk mice were taken using
Faxitron X-ray system (Faxitron X-Ray). Femora and ver-
tebrae (L3) were scanned using a CT (Scanco Medical)
system at 12 m of thickness, 55 kV of energy, and 145 A
of intensity. The data were reconstructed to produce 2D
and 3D images. BMD was determined by DXA using the
Lunar PIXImus2 densitometer (GE).
Quantitative real-time RT-PCR
RNA was isolated from ribs and femora from weanling
mice (P14 and P21) and femora and lumbar vertebrae from
adult mice (10–12 wk) using the MicroFastTrack 2.0 Kit
(Invitrogen). cDNA was synthesized using the SuperScript
Preamplification System (Invitrogen). PCR reactions, data
quantification, and analysis were performed according to
the manufacturer’s protocol (Applied Biosystems). Taq-
man primers and probes used in this study were as follows:
Bmpr1a, Mm00477650_m1 (64 bp); runt-related transcrip-
tion factor 2 (Runx2), Mm00501578_m1 (115 bp); osterix
(Sp7), Mm00504574_m1 (137 bp); bone sialoprotein (Bsp),
Mm00492555_m1 (98 bp); alkaline phosphatase (Akp2),
Mm00475831_m1 (141 bp); osteocalcin (Bglap2),
Mm01741771_g1 (77 bp); metalloproteinase-9 (Mmp9),
Mm00600163_m1 (107 bp); cathepsin K (Ctsk),
M m 0 0 4 8 4 0 3 6 _ m 1 ( 8 4 b p ) ; T R A C P ( T r a c p ) ,
M m 0 0 4 7 5 6 9 8 _ m 1 ( 7 9 b p ) ; R A N K L ( R a n k l ) ,
Mm00441908_m1 (69 bp); osteoprotegerin (Opg),
Mm00435452_m1 (119 bp). Values were normalized to
Gapdh using TaqMan Rodent GAPDH Control Reagents
(Applied Biosystems). All measurements were performed
in triplicate and analyzed using the 2−Ct method.(16)
Ex vivo culture of calvarial bone
Untreated cKO calvaria were collected from newborn
mice (Cre+, Bmpr1afx/fx), bisected at the sagittal suture,
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and cultured in modified BGJ (Invitrogen) supplemented
with ascorbic acid (50 mg/ml; Sigma) and 5% FBS (Life
Technologies) for the first 24 h in culture. One hemicalvaria
from each pair was treated with 4-hydroxyl (4-OH) TM
(100 ng/ml; Sigma) for 5 days. The medium was changed
daily.
Serum examination
Serum was collected from 22-wk-old mice. Circulating
serum levels of osteocalcin (BT-470; Biomedical Technolo-
gies), pyridinoline (8019; Quidel), RANKL, and OPG
(MBN-41K-1RANKL and MBN-41K-1OPG, respectively;
Millipore) were measured according to the manufacturer’s
instructions.
Statistical analysis
All results are expressed as mean ± SD. Student’s t-tests
were used to compare data between control and cKO mice;
p < 0.05 indicates significance.
RESULTS
Tissue specificity and efficiency of Cre recombinase
in Col1-CreERTM mice
Both developmental and remodeling stages are crucial
for understanding bone biology. In this study, we chose two
different stages, weanling (P21) and adult (22 wk), and con-
ditionally knocked out BMP signaling through BMPRIA in
FIG. 1. Col1-CreERTM transgenic mice. (A) TM-inducible Cre fusion protein Cre-ERTM under the control of a 3.2-kb mouse
procollagen 1(I) promoter (Col1-CreERTM). (B) TM administration schedule during weanling (P21) stage. TM was injected intra-
peritoneally into nursing females from P2 to P20 every 3 days. Both control mice (Cre−, Bmpr1afx/fx) and cKO mice (Cre+, Bmpr1afx/
fx) received TM. (C) TM administration schedule during adult (22 wk) stage. TM was injected intraperitoneally into adults from 8 to
22 wk, twice a week. Both controls and cKO received TM. (D) Quantitative real-time RT-PCR shows reduced expression of Bmpr1a
in femora and lumbar vertebrae from 10- to 12-wk mice and femora and ribs from P14 mice after recombination. *Statistically
significant difference between cKO and control from three independent experiments (mean ± SD, t-test; *p < 0.01). Similar results were
obtained from femora at P21. (E) BMPRIA protein in femora from 10- to 12-wk mice assessed using rabbit polyclonal antibodies
against BMPRIA exposed with DAB (brown). Nuclei were stained with hematoxylin. DAB+ cells per total cells are shown. *Statistically
significant difference between cKO (8%) and control (48%) in pooled data from three independent experiments (mean ± SD, t-test;
*p < 0.01). Similar results were obtained from lumbar vertebrae at the same stage and femur at P21. Bars, 50 m. (F) ROSA26 Cre
reporter mice showed Cre activity in osteoblasts but not in chondrocytes at P21. Cre-dependent DNA recombination was detected by
-galactosidase (-gal) staining (a). Cortical bone (b) and trabecular bone (c) are shown. Osteoclasts were negative for -gal (d). Bars:
1 mm (a), 50 m (b and c), and 20 m (d). (G) ROSA26 Cre reporter mice showed Cre activity in osteoblasts and osteocytes in
trabecular bone area (a) and cortical bone area (b) at 22 wk. Bars: 200 (a) and 100 m (b).
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osteoblasts using a TM-inducible Cre-loxP system under
the control of a 3.2-kb type I collagen promoter (Col1-
CreERTM; Figs. 1A–1C).
Expression levels of Bmpr1a in cKO bones as deter-
mined by quantitative RT-PCR were significantly reduced
>70% both in the weanling and adult stages (Fig. 1D).
BMPRIA in cKO 22-wk femora decreased 84% in osteo-
blasts and osteocytes by immunostaining (Fig. 1E). Similar
results were obtained from 22-wk lumbar vertebrae and
P21 femora (data not shown). Cre efficiency and the speci-
ficity of Col1-CreERTM expression were confirmed by -gal
staining using R26R mice.(14) In P21 femora, -gal staining
was observed in trabecular bone, as shown in the epiphysis
and metaphysis (Fig. 1F, a), and in cortical bone (Fig. 1F,
b). Staining was detected in immature periosteal cells, os-
teoblasts, and osteocytes (Fig. 1F, b) but not in chondro-
cytes (Fig. 1F, c) or soft tissues (Fig. 1F, a). Cre negative
controls administered TM (Col1-CreERTM−, TM+) and Cre-
positive mice not given TM (Col1-CreERTM+, TM−) showed
no -gal staining (data not shown). In addition, no Cre
activity was detected in osteoclasts as shown by staining for
-gal and H&E (Fig. 1F, d). These results show that the TM
administration delivered through milk specifically and effi-
ciently disrupts BMPRIA in osteoblasts and osteocytes in
weanling stages. Similarly, Cre activity was also detected in
osteoblasts and osteocytes in trabecular and cortical bone at
22 wk (Fig. 1G, a and b, respectively).
Increased bone mass in Bmpr1a cKO mice
Morphologically, cKO mice appeared normal both at P21
and 22 wk with no significant difference in body weight or
length compared with controls (data not shown). At P21,
X-ray analyses showed rib flaring (Fig. 2A, a) and a modest
FIG. 2. Relative BMD shown by X-ray at
P21 (A) and 22 wk (B). (A) White arrows
indicate rib flaring (a) and increased ra-
diodensity of metaphysis in femora (c) in P21
cKO mice. (B) Radiodensity of cKO bones
was notably increased in spines, tails, and
ribs but not in femora and skulls at 22 wk.
White arrows indicate calvarial bones where
sections were prepared (Fig. 3B, c and d).
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increase in radiodensity of tail trabeculae (Fig. 2A, b) and
femur metaphysis (Fig. 2A, c). H&E staining showed that
trabecular bone in the epiphysis and metaphysis of femur,
tibia, humerus, and vertebrae (tail) were dramatically in-
creased in cKO mice (Fig. 3A). Intramembranous calvarial
bones of cKO mice were thicker than those of controls with
increased woven bone (Fig. 3A, f and g). BMD measured
by DXA was significantly increased in ribs (control: 0.0152
g/cm2, cKO: 0.0163 g/cm2; p < 0.05), consistent with the
X-ray image (Fig. 2A, a). These results show increased
bone mass in both endochondral (femur, tibia, humerus,
and tail) and intramembranous (calvaria) cKO bones at P21
(Figs. 2A and 3A).
At 22 wk, rib flaring was also noted by X-ray in cKO mice
(Fig. 2B) similar to P21 mice (Fig. 2A), and radiodensity in
cKO bones including spine, tail, and rib cage was dramati-
cally increased (Fig. 2B), consistent with a significant in-
crease in BMD (Fig. 4A). H&E staining showed increased
bone mass in vertebrae and ribs (Fig. 3B, b and e, respec-
tively) where radiodensity was increased (Fig. 2B). How-
ever, the cKO femora appeared to be similar to controls by
X-ray analysis (Fig. 2B), H&E staining (Fig. 3B, a), and
DXA (Fig. 4A). Although cKO calvaria appeared un-
changed in X-rays (Fig. 2B), H&E staining showed a
smaller bone marrow cavity in cKO calvaria compared with
controls (Fig. 3B, c), which probably resulted in the signif-
icant increase in BMD observed (Fig. 4A). These results
show that bone mass is also increased in cKO mice during
adult stages with some variation by site.
We further examined trabecular and cortical bone inde-
pendently by CT. In vertebral trabecular bone, in addition
to a significant increase in tissue density (Table 1), bone
volume (BV/TV) and trabecular thickness of cKO bones
significantly increased 90% and 104% compared with con-
trols, respectively (Table 1), which is shown by the 3D re-
construction (Fig. 4B). In cKO femora, tissue density of
trabecular bone was significantly increased by a small
amount (Table 1), suggesting that trabecular bone is in-
creased in cKO mice to varying degrees by site. On the
other hand, in cKO femoral cortical bones, there were sta-
tistically significant differences in the adult cKO femora in
cortical porosity (increased), apparent density (decreased),
and tissue density (decreased) as noted in Table 2. These
differences are apparent in the 2D reconstruction (Fig. 4B)
and by H&E staining (Fig. 3B, a). Because Cre recombina-
tion is observed in cortical bones (Fig. 1G, b), these results
FIG. 3. Bone histology in Bmpr1a cKO mice at P21 (A) and 22 wk (B). (A) H&E staining of femora (a), tibia (b), humerus (c),
epiphysis of humerus (d), tails (e), and calvaria (f and g). Boxes in f are magnified in g. Bone mass was increased in cKO bones. Bars:
2 mm (a, b, and e), 1 mm (c and f), 500 m (d), and 200 m (g). (B) H&E staining of femora cortical bone (a), lumbar (L3) trabecular
bone (b), calvaria (c and d), and ribs (e). Bone mass was increased in L3 trabecular bone but not in femoral cortical bone. Boxes in c
are magnified in d. Bars: 1 mm (a, b, and e), 500 m (c), and 250 m (d).
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suggest that a decrease in BMPRIA signaling may be lead-
ing toward a “trabecularization” of cortical bone. Taken
together, P21 and 22-wk data suggest that Bmpr1a defi-
ciency in osteoblasts increased bone mass mainly by in-
creasing trabecular bone during both modeling and remod-
eling phases with some variation by site.
Reduced bone formation and resorption in Bmpr1a
cKO bones
Bone mass is determined by the balance between forma-
tion and resorption. To further study the trabecular bone
phenotype in cKO mice, these two factors were measured
by static and dynamic histomorphometry. We chose 22-wk
trabecular bones in femora and vertebrae because peak
bone mass and strength in the mouse are achieved after 20
wk, with dynamic changes in both material and geometric
properties.(10) Dynamic analysis showed a reduction of
bone formation (BFR/BS) and mineral apposition rate
(MAR) in trabecular bone of cKO femora (Fig. 5A). Dye
deposition showed double lines in trabecular bone of con-
trol femora but did not in cKO (Fig. 5B). No significant
decrease of N.Oc/T.Ar was observed in the femora trabec-
ulae (control: 123.1 ± 30.8, cKO: 119.1 ± 15.6). Bone volume
(BV/TV) and trabecular thickness (Tb.Th) were more in-
creased in cKO vertebrae than femora by static bone his-
tomorphometry (data not shown), consistent with the re-
sults from CT analysis (Table 1). Osteoclast number per
bone area (N.Oc/T.Ar) as determined by static analysis
with TRACP staining was significantly reduced in verte-
brae (L3) of cKO mice (Fig. 5C). These results suggest that
both bone formation and resorption were reduced by loss
of BMPRIA signaling with some variation by site.
We next examined formation and resorption by measur-
ing expression and serum levels of markers. RNA was ex-
tracted from weanling (P14) or adult (10–12 wk) mice (Figs.
1B and 1C). In adult vertebrae, expression levels of forma-
tion markers, Runx2 (Cbfa1) and Bsp, were significantly
reduced by ∼60% (Fig. 6A), and resorption markers Mmp9,
Ctsk, and Tracp were all significantly reduced >50% (Fig.
6B), consistent with the reduction in osteoclast number
stained by TRACP (Fig. 5C). However, formation markers
Sp7 (osterix) and Akp2 (alkaline phosphatase) were un-
changed. Similar results were obtained from femora at this
stage (data not shown). In weanling ribs where increased
radiodensity was observed (Fig. 2A, a), bone formation
markers were unchanged significantly (data not shown);
however, Tracp significantly decreased by 40% (Fig. 6D).
Osteoblasts regulate osteoclastogenesis by producing
RANKL, an osteoclast differentiation factor, and osteopro-
tegerin (OPG), a decoy receptor for RANKL.(17–19) During
adult stages, the expression of Rankl and Opg were signifi-
cantly decreased and increased, respectively (Fig. 6C), re-
sulting in a significant reduction of the ratio of Rankl to
Opg by 70% (Fig. 6C). Similar results were obtained from
weanling stages, beause the expression of Opg significantly
increased by 50%, and the ratio of Rankl to Opg signifi-
cantly decreased by 35% (Fig. 6D). Because RANKL
stimulates osteoclastogenesis, whereas OPG inhibits it,
these results suggest that osteoclastogenesis is decreased
both in weanling and adult stages. Serum levels of the for-
mation marker osteocalcin were significantly increased in
adult cKO mice (data not shown), consistent with dramati-
cally increased radiodensity at 22 wk (Fig. 2B). On the
other hand, the resorption marker pyridinoline, RANKL,
and the ratio of RANKL/OPG were nonsignificantly re-
duced in older mice (data not shown), partly because TM
administration confounds straightforward interpretation of
serum markers. It is also possible that timing of collecting
serum is crucial for monitoring biological changes, because
expression levels of resorption markers, Rankl, and Opg
changed at earlier stages (10–12 weeks). Overall data sug-
gest that resorption markedly decreases in cKO bones even
though formation is somewhat reduced or unchanged, re-
sulting in a net increase in bone mass.
To confirm the effect of BMP signaling on osteoclasto-
genesis through the RANKL–OPG pathway observed both
in weanling and adult stages, we next set up a tissue culture
system using newborn calvaria. Untreated cKO calvarial
bones were collected from newborn mice (Cre+, Bmpr1afx/
fx), bisected, and cultured with or without 4-OH TM (100
ng/ml). Cre-dependent DNA recombination using this
method was confirmed by -gal staining of calvarial bones
from R26R mice (Fig. 7A), and expression of Bmpr1a was
FIG. 4. Increased bone mass in cKO bones at 22 wk. (A) BMD
was determined by DXA using lumbar (L3), tails, ribs, femora,
and skulls. Values are expressed as mean ± SD (control, n  8;
cKO, n  10). *Statistically significant difference between control
and cKO (mean ± SD, t-test; *p < 0.01). (B) Reconstructions of
bone structure from CT. Cortical bone in femora and trabecular
bone in lumbar vertebrae (L3) are shown. Trabecular bone was
dramatically increased in cKO vertebrae (L3).
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significantly reduced 78% in cKO (Cre+, Bmpr1afx/fx,
TM+) compared with controls (Cre+, Bmpr1afx/fx, TM−;
Fig. 7B). Expression levels of resorption markers Mmp9,
Ctsk, and Tracp were significantly reduced >60% in cKO
compared with controls (Fig. 7C). Rankl expression was
reduced 41%, and Opg was significantly increased 12%,
resulting in a 50% reduction of the ratio of Rankl to Opg in
the treated group, which was significant (Fig. 7D). There
were no significant differences in these expression levels
between TM-treated (Cre−, Bmpr1afx/fx, TM+) and non-
treated Cre negative bone (Cre−, Bmpr1afx/fx, TM−) using
littermate controls (data not shown). These results suggest
that Bmpr1a-deficient osteoblasts reduced osteoclastogen-
esis through the RANKL–OPG pathway ex vivo, which
corroborates in vivo results.
DISCUSSION
Osteoblasts, BMP signaling, and bone mass
By using a 3.2-kb mouse procollagen 1(I) promot-
er,(9) we showed that reduction in BMP signaling through
BMPRIA in osteoblasts increased bone mass both in P21
and 22-wk mice. We also observed increased bone mass in
another conditional Bmpr1a knockout mouse (data not
shown) using Col13.6-Cre mice.(20) These bone phenotypes
are consistent with our previous report that showed in-
creased bone volume (BV/TV) at 10 mo by loss of BMP
signaling in osteoblasts using Og2-Cre mice, but it is not
consistent with the 3-mo mice, which showed decreased
bone mass.(8) The bone phenotype observed in Bmpr1a-
deficient mice with Og2-Cre(8) was milder than that with
Col1-CreERTM. These discrepancies may be caused by dif-
ferences in the timing of recombination between promot-
ers. Aubin(21) described characteristics of osteoblasts that
change along with their maturation; thus, the effects of dis-
rupting BMPRIA signaling may be influenced by the stages
of osteoblastic maturation. In Col1-CreERTM mice, Cre ac-
tivity was detected in immature periosteum wrapping
growth plates, in osteogenic centers, and in bone collars
during embryonic stages (data not shown). Therefore,
Col1-CreERTM mice can induce recombination earlier in
osteoblastogenesis, including in pre-osteoblasts, compared
with Og2-Cre mice, which could explain why the Bmpr1a-
deficient mice using Og2-Cre mice did not change expres-
sion levels of early osteogenic markers Runx2 and Bsp.(8)
These in vivo experiments taken together support in vitro
evidence(21) and imply that the response of osteoblasts to
BMP signaling differs both by age and differentiation stage.
Further studies of embryonic and older mice using Col1-
CreERTM mice and comparisons of the bone phenotype in
Bmpr1a deficiency among different osteoblast-specific Cre
mice are desired to address the diverse function of BMP
signaling.
BMP signaling and osteoclastogenesis
Mouse genetic models using BMP ligands and antago-
nists instead of receptors were recently reported. Overex-
pression of Bmp4 in osteoblasts reduced bone mass at
E18.5 with upregulation of osteoclastogenesis.(22) Overex-
pression of Noggin, an antagonist of BMP2 and BMP4, in
osteoblasts increased bone mass with reduced osteoclast
number (N.Oc/BS) and osteoclastogenesis both at E17.5
and 3 wk.(22) These studies are consistent with our findings,
because BMP2 and BMP4 are potent agonists of BMPRIA.
Taken together with our results, these studies suggest that
BMP signaling in osteoblasts negatively regulates bone
mass by upregulating osteoclastogenesis.
Reduction in osteoclast number (Fig. 5C) and expression
levels of functional markers (Mmp9, Ctsk, and Tracp) (Fig.
6B) showed downregulated osteoclastogenesis in cKO
mice, which may direct rib flaring (Fig. 2). The reduction of
TABLE 2. CORTICAL BONE (FEMUR) MEASUREMENT BY CT
Parameters (unit) Control cKO
Subperiosteal area (mm2) 1.95 ± 0.44 1.73 ± 0.22
Subendosteal area (mm2) 0.73 ± 0.22 0.64 ± 0.12
Segmented bone area (mm2) 1.18 ± 0.22 1.04 ± 0.12
Periosteal perimeter (mm) 5.09 ± 0.54 4.84 ± 0.34
Endosteal perimeter (mm) 3.15 ± 0.45 2.99 ± 0.36
Cortical porosity (%) 0.033 ± 0.01 0.05 ± 0.02
Cortical thickness (mm) 0.31 ± 0.02 0.29 ± 0.03
Apparent density (mg/cm3 HA) 1328.0 ± 15.0 1275.4 ± 34.4*
Tissue density (mg/cm3 HA) 1490.46 ± 19.83 1457.67 ± 28.63†
Data are mean ± SD; n  7 (Control); n  10 (cKO). Significant dif-
ferences are indicated between control and cKO (Student’s t-test, *p <
0.005; †p < 0.05).
HA, hydroxyapatite.
TABLE 1. TRABECULAR BONE MEASUREMENT BY CT
Parameters (unit)
Spine (L3) Femora
Control cKO Control cKO
BVF (BV/TV) (%) 35.7 ± 12.6 67.9 ± 14.5* 49.0 ± 15.8 59.7 ± 8.6
Trabecular thickness (mm) 61.9 ± 7.0 126.4 ± 52.2* 80.9 ± 13.1 108.3 ± 16.6*
Trabecular number (1/mm) 5.0 ± 0.9 6.9 ± 0.6* 6.8 ± 1.4 6.9 ± 1.0
Trabecular spacing (mm) 215.9 ± 38.7 124.4 ± 17.9* 129.3 ± 24.7 116.3 ± 31.5
Connectivity density (1/mm3) 250.2 ± 75.0 169.3 ± 83.7† 232.7 ± 71.5 177.7 ± 49.0
Apparent density (mg/cm3 HA) 402.9 ± 107.3 750.0 ± 159.1* 561.6 ± 135.3 675.4 ± 79.5
Tissue density (mg/cm3 HA) 1041.9 ± 51.6 1093.7 ± 29.2† 1066.4 ± 30.1 1109.8 ± 24.3†
Data are mean ± SD; n  7 (control); n  10 (cKO). Significant differences are indicated between control and cKO (Student’s t-test, *p < 0.005;
†p < 0.05).
BVF, bone volume fraction (%); BV, trabecular bone volume (mm3); TV, total volume selected for analysis (mm3); HA, hydroxyapatite.
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osteoclastogenesis in cKO mice is presumably caused by
the defect in osteoblasts, because the 3.2-kb type I collagen
promoter directed Cre recombination in osteoblasts but not
osteoclasts (Fig. 1F). Osteoblasts regulate osteoclast by ex-
pressing RANKL, an osteoclast differentiation factor, and
OPG, a decoy receptor for RANKL.(17–19) The link be-
tween BMP signaling and the RANKL–OPG pathway has
not been studied in vivo, because this signaling was un-
changed in mice overexpressing Noggin or Bmp4 in osteo-
blasts using the 2.3-kb type I collagen promoter(22) and
knocking out BMPRIA using osteocalcin promoter (Og2-
Cre mice).(8) This study is the first in vivo evidence showing
that loss of BMP signaling reduces osteoclastogenesis by
downregulating RANKL and upregulating OPG. Because
the 2.3-kb type I collagen and osteocalcin promoter are first
activated in mature osteoblasts,(20,23) it is possible that im-
mature osteoblastic stages, where the 3.2-kb type I collagen
promoter is active, are crucial for regulating osteoclasto-
genesis through the RANKL–OPG pathway.
BMP signaling, bone formation, and mineralization
Bone formation rate (BFR/BS) in femoral trabecular
bone was reduced in 22-wk mice by loss of function of
BMPRIA in osteoblasts (Fig. 5A), consistent with the pre-
vious report.(8) Overexpression of Noggin in osteoblasts
also reduced the formation rate at P21.(22) These facts sug-
gest that BMP signaling is critical for bone formation in
vivo, which supports in vitro evidence that BMPs induce
osteogenesis. However, in Bmpr1a cKO mice, the reduction
of formation rate in femora was more severe than that in
vertebrae, and mineral apposition rate (MAR) was reduced
in femora but not in vertebrae. These results suggest that
the effect BMP signaling has on bone formation may differ
in a site-specific manner in vivo, which can explain varia-
tions in changes in BMD and volume in cKO bones as
determined by X-ray, DXA, and CT. Further study is
necessary to understand the mechanism of the site specific-
ity in vivo, which would be difficult to assess in vitro.
In addition, changes noted in the cortices were not con-
sistent with findings in the trabeculae. One of the major
contextual differences that could contribute to the unique
osteotropic response to BMP signaling in the trabeculae
compared with other sites such as cortical bone, perichon-
drium, and skeletal muscle (ectopic) is the immediate jux-
taposition of trabecular osteoblasts to the hematopoietic
lineage. The 3.2-kb promoter used in Col1-CreERTM mice
is active in pre-osteoblasts, osteoblasts, periosteum, and os-
teocytes widely throughout all bones examined. Site-
specific promoters for Cre recombination could be devel-
oped to answer these questions.
BMD as determined by X-ray, DXA, and CT was in-
creased in cKO ribs, vertebrae, and tails at 22 wk (Figs.
2–4). These results indicate that loss of BMP signaling en-
hances bone mineralization. Interestingly, two in vitro stud-
ies have data that support our findings. One showed an
increase in mineralization by overexpressing truncated
BMPRIA without a kinase domain to block BMP signal-
ing.(24) Another showed an inhibition of mineralization by
adding exogenous BMP2 into culture.(25) Neither inter-
preted these results in their discussions. However, these
facts suggest that BMP signaling negatively regulates
mineralization in vivo. Another possibility is that loss of
BMPRIA signaling causes a decrease in bone resorption.
The existing matrix ages and continues to mineralize, simi-
lar to the proposed mechanism for the increase in BMD
observed in humans on bisphosphonate therapy.(26,27) In
addition, serum levels of osteocalcin increased (data not
shown), indicating an increased number of osteoblast and
FIG. 5. Morphometric markers for bone formation and resorp-
tion at 22 wk. (A) Dynamic (BFR/BS and MAR) analyses were
performed using trabecular bone of femora and lumbar vertebrae
(L3) from control (n  10) and cKO (n  10) mice. *Statistically
significant difference between control and cKO (t-test; *p < 0.05;
**p < 0.005; BFR/BS, bone formation rate over bone surface;
MAR, mineral apposition rate). (B) Dynamic histomorphometric
analysis of cKO bones by double label staining of trabecular bone
in femora with calcein and xylenol orange. Dotted and random
staining pattern was shown in cKO. White arrows indicate merg-
ing of double labeled staining in cKO bone. Bars: 100 m. (C)
Static histomorphometric analysis of L3 trabecular bone with
TRACP staining. Values are expressed as mean ± SD (control,
n  5; cKO, n  5). *Statistically significant difference between
control and cKO (mean ± SD, t-test; *p < 0.05). N.Oc/T.Ar, os-
teoclast number per bone area. Bars: 100 m.
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osteocytes, which is consistent with increased bone mass in
Bmpr1a cKO mice. This fact may also contribute to in-
creased mineralization in cKO bones. Further study is nec-
essary to address the mechanism by which BMP signaling
controls bone mineralization.
BMP signaling, endogenous bone, and ectopic bone
Osteoblasts and chondrocytes both affect bone mass and
are the predominant cell types in bone and cartilage, re-
spectively. However, the difference in molecular mecha-
nisms by which BMP signaling regulates these cell types to
control bone mass is largely unknown, partly because of a
lack of appropriate mouse genetic models. In this study, we
found that osteoblasts lacking Bmpr1a fail to support os-
teoclastogenesis, leading to an increase in endogenous bone
mass. Thus, we propose that BMP signaling in osteoblasts
has dual functions to balance bone mass; it enhances bone
formation by osteoblasts and enhances bone resorption by
supporting osteoclastogenesis. However, studies focusing
on BMP receptors in chondrocytes suggest that these cells
respond to BMP signaling by increasing bone mass during
the endochondral formation process.(15,28) Mice overex-
pressing Bmp4 in mesenchymal cells and chondrocytes in-
crease bone mass, whereas overexpression of Noggin in
those cells decreases bone mass.(22,29) In addition, recent
mouse studies in which Cre expression is driven by a pro-
moter in mesenchymal cells and chondrocytes (Prx1-
Cre)(30,31) showed that the disruption of BMP ligands in
these cells impaired osteogenesis, resulting in reduced bone
mass, and blocked fracture healing, which follows endo-
chondral bone formation. Taken together, we propose that
BMP signaling in chondrocytes increases bone mass but
BMP signaling in osteoblasts restrains endogenous bone
mass.
BMPs given subcutaneously induce ectopic bone forma-
tion.(1) Human genetics showed that enhanced BMP signal-
ing by a point mutation in ACVR1, another BMP type I
receptor, causes fibrodysplasia ossificans progressiva (FOP)
with ectopic bones in muscle.(32) These ectopic bones in
muscle may form primarily because of the effect of BMP
signaling on chondrocytes as we discussed above, because
ectopic bone formation follows an endochondral formation
pattern. The FDA approved BMP2 and BMP7 for clinical
use to improve fracture healing.(33) However, our finding of
increased bone mass by loss of BMPRIA is unexpected and
contrary to the rationale behind clinical applications of
BMPs in orthopedics. Current clinical data supporting their
use is underdeveloped(3,4); this may be in part because of a
lack of understanding of the variable effects BMPs have on
different cell types in the skeleton including chondrocytes,
osteoblasts, and osteoclasts. In addition, species differences
might also play a role in the lack of efficacy in human
clinical trials. Whereas much of the in vitro and in vivo
analyses have been done on mouse cells and mouse models,
demonstration of the effects of BMPs on human cells in
vitro are modest because of species differences.(34)
FIG. 6. Expression levels of bone formation and resorption markers during adult and weanling stages. RNA was extracted from
vertebrae of 10- to 12-wk mice for adult stages and ribs of P14 for weanling stages. (A) Quantitative RT-PCR for bone formation
markers (Runx2, Sp7, Bsp, Akp2, and Bglap2) during adult stages. Expression levels of both Runx2 and Bsp were significantly reduced
in cKO. (B) Quantitative RT-PCR for bone resorption markers expressed by osteoclasts (Mmp9, Ctsk, and Tracp) during adult stages.
These expression levels were all reduced over 50% in cKO. (C) Quantitative RT-PCR for Opg and Rankl expressed by osteoblasts and
relative ratio of Rankl to Opg expression levels during adult stages. The expression of Rankl was significantly reduced by 60%, and Opg
was significantly increased by 80%, resulting in a significant reduction in the ratio of Rankl to Opg by 70% in cKO. (D) Quantitative
RT-PCR for bone resorption markers (Mmp9, Ctsk, and Tracp) and RANKL–OPG pathway (Opg and Rankl), and relative ratio of
Rankl to Opg expression levels during weanling stages. The expression of Tracp decreased by 40% and Opg increased by 50%, both
significantly. The ratio of Rankl to Opg expression levels significantly decreased 35%. Similar results were obtained from femora during
adult stages. *Statistically significant difference between cKO and control from three independent experiments in A–D (mean ± SD,
t-test; *p < 0.05; **p < 0.001).
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Future work will focus on the mechanisms by which loss
of BMPRIA signaling in osteoblasts impacts remodeling.
This may best be performed in older animals, perhaps chal-
lenged with ovariectomy, orchiectomy, fracture, or immo-
bilization.
In conclusion, this study shows that loss of BMP signaling
by BMPRIA directs osteoblasts to increase bone mass pri-
marily in trabecular bone in part by downregulating osteo-
clastogenesis through the RANKL–OPG pathway. In os-
teoblasts, BMPRIA is a signaling molecule that directs both
bone formation and resorption to reduce endogenous bone
mass in vivo.
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